Hormone Replacement Therapy (HRT)
Hormone Replacement Therapy Improves Bone Mineral Loss After Salpingo-oophorectomy for Ovarian CancerApril 11, 2016
In patients who undergo risk-reducing salpingo-oophorectomy, BMD screenings are underutilized in spite of the prevalence of bone mineral loss in this population. Hormone replacement therapy can address BMD loss in these women.
The impact of hormone replacement therapy (HRT) use on breast cancer risk varies according to patient race/ethnicity, body mass index (BMI), and breast density, researchers have learned.
HRT-linked risk up for white, Asian, Hispanic women; for low/normal BMI and dense breasts.
ONS Connections: Pretreatment depression, anxiety, and poor physical functioning associated with non-adherence to hormonal therapy in breast cancer patientsNovember 18, 2012
Taking a lower percentage of prescribed doses of hormonal therapy was associated with higher pre-therapy levels of depression and anxiety and with poorer physical functioning.
Risk increased with estrogen, estrogen progesterone; no increase in fatal breast cancer.
Women who used estrogen after hysterectomy appear to be nearly 25% less likely to develop breast cancer and nearly 63% less likely to die from it.
Discontinuing hormone therapy may lead to tumor regression in breast cancer, indicate the results of a new study.
The use of estrogen-only after hysterectomy lowers the risk of breast cancer, but largely in groups already at low risk of breast cancer.
The first drop in mammography rates since 1987 among age-eligible women occurred in 2005, and at least partial blame can be pinned on the decline in the use of hormone therapy.
Postmenopausal women who use estrogen do not increase their risk for lung cancer mortality, according to a study published in The Journal of the National Cancer Institute (2010 Aug 13. [Epub ahead of print]).
Breast cancer risk increases with long-term use of hormone therapies, according to a study that analyzed the California Teachers Study.
Breast cancer risk in postmenopausal women varies depending on the type of progestin used in hormone replacement therapy, according to a study published in Cancer Prevention Research (2010 Aug 10 [Epub ahead of print]).
Short-term hormonal therapy increases overall survival in patients with prostate cancer, according to a study presented at the 2010 Genitourinary Cancers Symposium.
GPs should advise women to continue taking HRT, despite claims linking it to breast cancer, according to an expert on the menopause.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Use of Checkpoint Inhibitors in Urothelial Carcinoma
- Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Colorectal Cancer Risk Higher With Poor Metabolic Health vs Increased Weight
- Best Approach to Infection and Tumor Treatment: Contain or Eliminate?
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|